Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Controlling Noise and Environmental Disturbances – V 2.0

Posted on By

BA-BE Studies: SOP for Controlling Noise and Environmental Disturbances – V 2.0

Standard Operating Procedure for Control of Noise and Environmental Disturbances in BA/BE Clinical Facilities

Department BA-BE Studies
SOP No. SOP/BA-BE/147/2025
Supersedes SOP/BA-BE/147/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized approach for minimizing noise and controlling environmental disturbances within the clinical facility during the conduct of BA/BE studies, in order to maintain volunteer comfort, reduce bias, and ensure the integrity of collected clinical and bioanalytical data.

2. Scope

This SOP applies to all clinical operations conducted at BA/BE study units, including volunteer housing,

dosing rooms, sample collection areas, and monitoring spaces.

3. Responsibilities

  • Facility Manager: Ensures infrastructure-related controls are in place and functional (e.g., noise insulation, air filters).
  • Clinical Operations Team: Maintains a controlled and calm environment during study periods.
  • Security Supervisor: Prevents unauthorized access or disruptions from external sources.
  • Quality Assurance (QA): Periodically audits environmental controls and logs deviations.

4. Accountability

The Head of Clinical Operations is accountable for ensuring that the noise and environmental standards outlined in this SOP are adhered to across all active BA/BE studies.

See also  BA-BE Studies: SOP for Handling Expired Reference Products - V 2.0

5. Procedure

5.1 Identification of Noise and Disturbance Sources

  1. Conduct an Environmental Risk Assessment (Annexure-1) for all clinical zones before each study.
  2. Identify possible sources of noise including:
    • Generator or HVAC systems
    • Mobile phones and intercoms
    • Heavy movement of trolleys or beds
    • Subject verbal communication and audio/video devices
  3. Identify light or temperature fluctuations that could disturb subjects.

5.2 Infrastructure Controls

  1. Install noise-insulating panels in subject dormitories and dosing rooms.
  2. Ensure doors are fitted with rubber seals and close gently without slamming.
  3. Air conditioning units and generators must be serviced quarterly to reduce mechanical noise.
  4. Maintain a Noise Control Equipment Maintenance Log (Annexure-2).

5.3 Operational Controls

  1. Restrict all loud conversations, mobile alerts, or announcements within clinical zones during dosing and monitoring windows.
  2. Prohibit entry of unauthorized personnel or vendors during active study hours.
  3. Assign a designated Environmental Compliance Officer per study to ensure real-time monitoring.
  4. Use soft-tread slippers for volunteers and trolleys with noise-absorbing wheels.

5.4 Environmental Monitoring

  1. Install sound level meters to measure decibel (dB) levels in:
    • Volunteer sleeping areas
    • Sample collection and processing rooms
  2. Maintain Annexure-3: Noise Monitoring Log with three daily readings (morning, afternoon, evening).
  3. Alert if readings exceed 60 dB during rest hours (10 PM – 6 AM).
See also  BA-BE Studies: SOP for Chain of Custody for Clinical Samples - V 2.0

5.5 Subject Briefing and Behavior Control

  1. Brief all volunteers on behavior guidelines:
    • Maintain silence during sampling or rest periods
    • Use earphones if watching videos during free time
    • Comply with designated quiet hours
  2. Display posters with environmental discipline instructions in vernacular and English.

5.6 Escalation and Corrective Action

  1. In case of major noise events (e.g., equipment malfunction or external construction):
    • Document immediately in Annexure-4: Environmental Incident Log
    • Notify the Clinical Operations Head
    • Activate alternate sleeping or dosing arrangements if prolonged
  2. Implement corrective and preventive action (CAPA) as needed.

5.7 Audit and Review

  1. QA to conduct quarterly audits using Annexure-5: Noise Compliance Checklist.
  2. Records to be archived in the Trial Master File for minimum of 5 years.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • QA: Quality Assurance
  • HVAC: Heating, Ventilation, and Air Conditioning
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Environmental Risk Assessment – Annexure-1
  2. Noise Control Equipment Maintenance Log – Annexure-2
  3. Noise Monitoring Log – Annexure-3
  4. Environmental Incident Log – Annexure-4
  5. Noise Compliance Checklist – Annexure-5
See also  BA-BE Studies: SOP for Study Timelines and Milestone Management - V 2.0

8. References

  • WHO Guidelines for Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • ICH E6(R2) – Good Clinical Practice

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Environmental Risk Assessment

Zone Identified Risks Control Measures Verified By
Volunteer Room Nearby generator noise Soundproof window panels Rajesh Kumar

Annexure-2: Noise Control Equipment Maintenance Log

Equipment Last Serviced On Next Due Remarks
Air Conditioner (Block B) 01/04/2025 01/07/2025 Working

Annexure-3: Noise Monitoring Log

Date Time Location Reading (dB) Recorder
16/04/2025 10:00 AM Dosing Room 52 Sunita Reddy

Annexure-4: Environmental Incident Log

Date Issue Zone Corrective Action Resolved On
15/04/2025 Construction noise from adjacent site Volunteer Dorm Subjects shifted to alternate wing 16/04/2025

Annexure-5: Noise Compliance Checklist

Audit Date Checked Areas Compliance Status Auditor Name
15/04/2025 Clinical Zones A & B Compliant Vinay Pawar

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Annexures added, expanded controls Environmental audit feedback QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Fed-Batch Cultivation Strategy in Bioreactor Operations – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version